Literature DB >> 33600439

Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats.

Margaret E Martinez1, Cristina Capella Gonzalez2, Devra Huey1, Mark E Peeples3,4, Douglas McCarty5, Stefan Niewiesk1.   

Abstract

Human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants and young children worldwide. The attachment (G) protein of RSV is synthesized by infected cells in both a membrane bound (mG) and secreted form (sG) and uses a CX3C motif for binding to its cellular receptor. Cell culture and mouse studies suggest that the G protein mimics the cytokine CX3CL1 by binding to CX3CR1 on immune cells, which is thought to cause increased pulmonary inflammation in vivo. However, because these studies have used RSV lacking its G protein gene or blockade of the G protein with a G protein specific monoclonal antibody, the observed reduction in inflammation may be due to reduced virus replication and spread, and not to a direct role for G protein as a viral chemokine. In order to more directly determine the influence of the soluble and the membrane-bound forms of G protein on the immune system independent of its attachment function for the virion, we expressed the G protein in cotton rat lungs using adeno-associated virus (AAV), a vector system which does not itself induce inflammation. We found no increase in pulmonary inflammation as determined by histology and bronchoalveolar lavage after inoculation of AAVs expressing the membrane bound G protein, the secreted G protein or the complete G protein gene which expresses both forms. The long-term low-level expression of AAV-G did, however, result in the induction of non-neutralizing antibodies, CD8 T cells and partial protection from challenge with RSV. Complete protection was accomplished through co-immunization with AAV-G and an AAV expressing cotton rat interferon α.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33600439      PMCID: PMC7891763          DOI: 10.1371/journal.pone.0246770

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  73 in total

1.  CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

Authors:  Tatiana Chirkova; Songbai Lin; Antonius G P Oomens; Kelsey A Gaston; Seyhan Boyoglu-Barnum; Jia Meng; Christopher C Stobart; Calvin U Cotton; Tina V Hartert; Martin L Moore; Assem G Ziady; Larry J Anderson
Journal:  J Gen Virol       Date:  2015-06-25       Impact factor: 3.891

2.  CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein.

Authors:  R A Tripp; L P Jones; L M Haynes; H Zheng; P M Murphy; L J Anderson
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

3.  Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice.

Authors:  Eric R Pozsgai; Danielle A Griffin; Kristin N Heller; Jerry R Mendell; Louise R Rodino-Klapac
Journal:  Mol Ther       Date:  2017-03-09       Impact factor: 11.454

4.  Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.

Authors:  Bo Liang; Barbora Kabatova; Juraj Kabat; David W Dorward; Xiang Liu; Sonja Surman; Xueqiao Liu; Annie Park Moseman; Ursula J Buchholz; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

5.  Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.

Authors:  Jennifer L Harcourt; Ruth A Karron; Ralph A Tripp
Journal:  J Infect Dis       Date:  2004-10-28       Impact factor: 5.226

6.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

7.  Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

Authors:  V A Fulginiti; J J Eller; O F Sieber; J W Joyner; M Minamitani; G Meiklejohn
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

8.  A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats.

Authors:  Jessica L Grieves; Zhiwei Yin; Adolfo Garcia-Sastre; Ignacio Mena; Mark E Peeples; Heidi P Risman; Hannah Federman; Marvin J Sandoval; Russell K Durbin; Joan E Durbin
Journal:  Vaccine       Date:  2018-05-18       Impact factor: 3.641

9.  CD8+ T cell responses in bronchoalveolar lavage fluid and peripheral blood mononuclear cells of infants with severe primary respiratory syncytial virus infections.

Authors:  Jojanneke Heidema; Michaël V Lukens; Wendy W C van Maren; Mariska E A van Dijk; Henny G Otten; Adrianus J van Vught; Desiree B M van der Werff; Sjef J P van Gestel; Malcolm G Semple; Rosalind L Smyth; Jan L L Kimpen; Grada M van Bleek
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

Review 10.  Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis.

Authors:  Renato T Stein; Louis J Bont; Heather Zar; Fernando P Polack; Caroline Park; Ami Claxton; Gerald Borok; Yekaterina Butylkova; Colleen Wegzyn
Journal:  Pediatr Pulmonol       Date:  2016-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.